Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 5, 2008

Invitrogen and Applied Biosystems to Be Called Life Technologies

  • Invitrogen reports progress with its integration plans regarding its pending merger with Applied Biosystems. New members have been appointed to the board of directors of the combined entity, which will be called Life Technologies.

    The company announced that three members of the Applied Biosystems’ board of directors have been named to the board of the new company. The new members are: George F. Adam Jr., chairman of Recondo Technology, Arnold J. Levine, Ph.D., professor at the Institute for Advanced Study, and William H. Longfield, retired chairman and CEO of C.R. Bard. They will join the nine current members of Invitrogen’s board of directors.

    Instruments and systems solutions will continue to be sold under the Applied Biosystems brand name, while the combined company’s broad offering of reagents will be sold under the Invitrogen brand name.

    “As we moved through the integration process and gained greater clarity around the vision for our joint company, the new management team felt that the Life Technologies name best symbolizes the promise of what we can accomplish together,” comments Greg Lucier, Invitrogen’s chairman and CEO. “When we receive European Commission clearance, we will be ready to enable research that will lead to more personalized medicine, safer food and water, and a healthier environment—in short, we will provide technologies that make life even better.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »